• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测入组成功率以优化临床试验资源分配。

Predicting accrual success for better clinical trial resource allocation.

作者信息

Ma Sisi, Wang Yinzhao, Wagner John, Johnson Steve, Pakhomov Serguei, Aliferis Constantin

机构信息

Institute for Health Informatics, University of Minnesota, Minneapolis, MN, 55455, USA.

Medical School, University of Minnesota, Minneapolis, MN, 55455, USA.

出版信息

Sci Rep. 2025 Jan 31;15(1):3879. doi: 10.1038/s41598-025-88400-x.

DOI:10.1038/s41598-025-88400-x
PMID:39890973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11785987/
Abstract

Accrual success is one key determining factor for the success of clinical trials. Global data analyses of all terminated trials reported that 55% of trials were terminated due to low accrual rates. Failure to meet accrual goals have a significant impact on costs for sponsors, academic institutions, investigators, and society at large. The ability to predict trial accrual success with high precision before the trial starts would be highly valuable, preventing the allocation of critical resources for trials unlikely to meet accrual goals. In the present study, we constructed a dataset for predicting clinical trial failure based on poor accrual using clinicaltrial.gov data containing information on 57,846 trials. Features of the dataset were informed by prior literature and constructed using data-driven natural language processing methods. We built predictive models for accrual failure using state-of-the-art supervised machine learning protocols and methods. Models resulted in good predictive performance that was stable over a 10-year time period, with predictive performance of cross-validation AUC = 0.744 (+/-0.018) and prospective validation AUC = 0.737 (+/-0.038). We also improved model calibration and examined model performance with the reject option. These modifications enable model translation into decision support tools for various real-world settings. To the best of our knowledge, this is the first study to develop models for predicting clinical trial failure due to accrual based on a large dataset with a comprehensive set of trial features.

摘要

入组成功是临床试验成功的一个关键决定因素。对所有已终止试验的全球数据分析表明,55%的试验因入组率低而终止。未能达到入组目标会对申办方、学术机构、研究者以及整个社会的成本产生重大影响。在试验开始前高精度预测试验入组成功的能力将非常有价值,可避免为不太可能达到入组目标的试验分配关键资源。在本研究中,我们使用clinicaltrial.gov上包含57,846项试验信息的数据构建了一个基于入组不佳预测临床试验失败的数据集。该数据集的特征参考了先前的文献,并使用数据驱动的自然语言处理方法构建。我们使用最先进的监督式机器学习协议和方法建立了入组失败的预测模型。模型具有良好的预测性能,在10年期间保持稳定,交叉验证AUC = 0.744(±0.018),前瞻性验证AUC = 0.737(±0.038)。我们还改进了模型校准,并使用拒绝选项检查了模型性能。这些改进使模型能够转化为适用于各种实际场景的决策支持工具。据我们所知,这是第一项基于包含全面试验特征的大型数据集开发因入组导致临床试验失败预测模型的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab50/11785987/37fc64fcca43/41598_2025_88400_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab50/11785987/57b8d2a34b7a/41598_2025_88400_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab50/11785987/85157d7f7ccd/41598_2025_88400_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab50/11785987/37fc64fcca43/41598_2025_88400_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab50/11785987/57b8d2a34b7a/41598_2025_88400_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab50/11785987/85157d7f7ccd/41598_2025_88400_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab50/11785987/37fc64fcca43/41598_2025_88400_Fig3_HTML.jpg

相似文献

1
Predicting accrual success for better clinical trial resource allocation.预测入组成功率以优化临床试验资源分配。
Sci Rep. 2025 Jan 31;15(1):3879. doi: 10.1038/s41598-025-88400-x.
2
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
3
Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.在资源匮乏地区,针对感染艾滋病毒的成人和青少年治疗失败时何时更换一线抗逆转录病毒治疗方案的最佳监测策略。
Cochrane Database Syst Rev. 2010 Apr 14(4):CD008494. doi: 10.1002/14651858.CD008494.
4
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
5
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
6
Atraumatic restorative treatment versus conventional restorative treatment for managing dental caries.非创伤性修复治疗与传统修复治疗在龋病管理中的比较
Cochrane Database Syst Rev. 2017 Dec 28;12(12):CD008072. doi: 10.1002/14651858.CD008072.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
8
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
9
Omega-3 fatty acids for depression in adults.成人抑郁症的ω-3脂肪酸治疗
Cochrane Database Syst Rev. 2015 Nov 5;2015(11):CD004692. doi: 10.1002/14651858.CD004692.pub4.
10
Fornix-based versus limbal-based conjunctival trabeculectomy flaps for glaucoma.用于青光眼的穹窿部结膜小梁切除术瓣与角膜缘部结膜小梁切除术瓣对比
Cochrane Database Syst Rev. 2015 Nov 25;11(11):CD009380. doi: 10.1002/14651858.CD009380.pub2.

本文引用的文献

1
Factors Affecting Success of New Drug Clinical Trials.影响新药临床试验成功的因素。
Ther Innov Regul Sci. 2023 Jul;57(4):737-750. doi: 10.1007/s43441-023-00509-1. Epub 2023 May 11.
2
The next generation of evidence-based medicine.循证医学的下一代。
Nat Med. 2023 Jan;29(1):49-58. doi: 10.1038/s41591-022-02160-z. Epub 2023 Jan 16.
3
Improving clinical trial design using interpretable machine learning based prediction of early trial termination.利用基于可解释机器学习的早期试验终止预测来改进临床试验设计。
Sci Rep. 2023 Jan 4;13(1):121. doi: 10.1038/s41598-023-27416-7.
4
A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes.一项多中心研究,探讨了乳腺癌、卵巢癌和结直肠癌易感基因中意义未明变异分类的临床影响。
Cancer Med. 2023 Feb;12(3):2875-2884. doi: 10.1002/cam4.5202. Epub 2022 Nov 24.
5
Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated clinical trials.资格标准内容的增长和国家癌症研究所(NCI)附属临床试验的累积失败。
Cancer Med. 2023 Feb;12(4):4715-4724. doi: 10.1002/cam4.5276. Epub 2022 Nov 18.
6
Prediction of clinical trial enrollment rates.临床试验入组率预测。
PLoS One. 2022 Feb 24;17(2):e0263193. doi: 10.1371/journal.pone.0263193. eCollection 2022.
7
Reporting bias in clinical trials: Progress toward transparency and next steps.临床试验中的报告偏倚:向透明化迈进及下一步措施。
PLoS Med. 2022 Jan 19;19(1):e1003894. doi: 10.1371/journal.pmed.1003894. eCollection 2022 Jan.
8
Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic.癌症临床试验参与在 COVID-19 大流行爆发一周年之际。
JAMA Netw Open. 2021 Jul 1;4(7):e2118433. doi: 10.1001/jamanetworkopen.2021.18433.
9
Predictive modeling of clinical trial terminations using feature engineering and embedding learning.使用特征工程和嵌入学习对临床试验终止进行预测建模。
Sci Rep. 2021 Feb 10;11(1):3446. doi: 10.1038/s41598-021-82840-x.
10
Recruitment and retention of participants in clinical studies: Critical issues and challenges.临床研究中参与者的招募与留存:关键问题与挑战
Perspect Clin Res. 2020 Apr-Jun;11(2):51-53. doi: 10.4103/picr.PICR_6_20. Epub 2020 May 6.